Kiromic and SEC settle over undisclosed clinical trial holds
The SEC said Tuesday that it settled charges filed against Kiromic BioPharma, a tiny immuno-oncology startup based in Texas, for failing to disclose clinical holds on two experimental cancer drugs...
View ArticleGSK terminates Phase 2 trial of HBV therapeutic vaccine
GSK has axed a Phase 2 study of a chronic hepatitis B therapeutic vaccine, adding to a string of treatment R&D hurdles for the liver infection. The termination of the study of GSK3528869 was the ...
View ArticleLilly removes body mass ranges from FDA label for weight loss drug
Eli Lilly has removed the commonly used clinical measure of body mass index from the FDA label for its weight loss drug Zepbound, a move that could give physicians greater leeway to decide who should ...
View ArticleOn heels of MariTide data, Danish obesity biotech discloses €80M Series A
Versant is out with its third obesity biotech of the year, leading an €80 million Series A for Antag Therapeutics, a Danish company developing a drug that uses a similar approach as Amgen's...
View ArticleGSK makes another ADC deal, this time with BioNTech's partner DualityBio
GSK is returning to China for another antibody-drug conjugate deal, and it's tapping into a company that already has alliances with BioNTech, Adcendo and others. The UK pharma is ...
View ArticleLilly wins head-to-head weight loss trial against Novo Nordisk
The market for first-generation weight loss treatments has been dominated by two major players, Eli Lilly and Novo Nordisk. But new data provide the clearest evidence yet that one may have an edge. On...
View ArticleAtea blueprints Phase 3 for hepatitis C combo after mid-stage win
Atea Pharmaceuticals touted data from a mid-stage trial studying its hepatitis C drug combo on Wednesday, announcing that it had hit both safety and efficacy primary endpoints. The 275-patient trial...
View ArticleDewpoint partners its ALS program, eyes JPM to raise a Series D
Molecular condensates startup Dewpoint Therapeutics has signed on its latest partner, this time forging a future for its ALS program with Mitsubishi Tanabe Pharma Corporation in a pact worth up to $480...
View ArticleRo’s weight loss business more than doubled in the last year. Now it’s trying...
With direct-to-patient services for obesity drugs facing scrutiny, the telehealth startup Ro is trying to prove that its online weight loss program is up to snuff. To that end, the startup released ...
View ArticleGSK partners with Rgenta on RNA-targeted small molecules for oncology, other...
GSK will team up with Boston-area biotech Rgenta Therapeutics to create oral small molecules that target RNA, the companies said Wednesday morning. The duo will discover and develop splice modulators...
View ArticleUpdated: CEO of UnitedHealth insurance unit shot and killed in New York in...
UnitedHealthcare CEO Brian Thompson was shot and killed in Midtown Manhattan Wednesday morning ahead of the insurer's investor day, according to the company and police. The New York Police Department...
View ArticleGeneDx bets that rare disease data can aid drug discovery
Two years ago, GeneDx was teetering. The genetic testing company had laid off 33% of its staff, shares were down 90% from a year prior, and some investors were skeptical of a turnaround plan. ...
View ArticleRelmada's rapid-acting NMDA depression drug expected to fail second Phase 3
Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. The study’s data monitoring committee said...
View ArticleAstraZeneca's new EVP of international amid China investigation; Janux’s...
Plus, news about Arrakis, Eli Lilly, Everest Medicines, Teva, Rondo Therapeutics, Trevi Therapeutics, Foresee Pharmaceuticals and Revolution Medicines: AstraZeneca taps new leader to run China...
View ArticleNovavax sells Czech facility to Novo Nordisk for $200M to cut costs
Novo Nordisk is buying a vaccine manufacturing factory from Novavax for $200 million to expand production of its current and future mammalian-based products, a spokesperson for the Danish drugmaker...
View ArticleSickle cell gene therapies included in new Medicaid access model
The Biden Administration said Wednesday that it has secured agreements with Vertex Pharmaceuticals and bluebird bio for their sickle cell disease gene therapies to be the first in a new access model...
View ArticleTrade group tells FDA that semaglutide is not too 'complex' for compounding
The Alliance for Pharmacy Compounding told the FDA last week that Novo Nordisk's weight loss medicine semaglutide is not too difficult to compound, pushing back against the Danish pharma's arguments...
View ArticleModerna defends pandemic prep as vaccine skeptics gain power
Moderna CEO Stéphane Bancel argued that the drug industry's efforts to prepare for a future pandemic are meant to protect Americans, defending the sector's work even as President-elect Donald Trump...
View ArticleNovo Nordisk budgets $409M for new quality control lab in Denmark
Novo Nordisk is spending DKK 2.9 billion ($409 million) to build a new quality control laboratory and will move existing operations into the site to create a “central hub.” The new 53,000-square meter...
View ArticleGSK, Zhifei extend shingles vaccine pact for less money
In a week of back-to-back new deals, GSK is extending its Shingrix agreement in China and adding a collaboration for its RSV vaccine Arexvy. But the changes mean the UK pharma could get millions of ...
View Article